[Methocarbamol in acute low back pain. A randomized double-blind controlled study].

Area of Science:

• Pharmacology
• Orthopedics
• Clinical Medicine

Background:

• Low back pain (LBP) is a prevalent health issue in industrialized nations.
• Regulatory restrictions on muscle relaxants, including Tetrazepam withdrawal, highlight the need for safe alternatives.
• Methocarbamol is an established treatment for LBP with myofascial components, yet recent clinical data is scarce.

Purpose of the Study:

• To re-evaluate post-hoc data from a 2002 clinical study on methocarbamol's efficacy for acute low back pain.
• To assess methocarbamol's effectiveness in patients experiencing lumbar spasms and mobility restrictions.

Main Methods:

• A randomized, placebo-controlled, multi-center study involving 202 patients with acute LBP and spasms.
• Patients received either oral methocarbamol (Ortoton®) or placebo for up to 8 days, with treatment cessation upon pain relief.
• Efficacy was measured using a visual analog scale (VAS) for pain, fingertip-to-floor distance, modified Schober's test for mobility, and patient/physician questionnaires.

Main Results:

• Significantly higher rates of complete pain relief in the methocarbamol group (44%) compared to placebo (18%).
• Methocarbamol treatment showed clear advantages in improving lumbar flexion and overall mobility, as assessed by objective measures and subjective reports.
• High patient (67%) and physician (70%) satisfaction with methocarbamol treatment efficacy, with no severe adverse events reported.

Conclusions:

• Oral methocarbamol is an effective and well-tolerated treatment for acute low back pain.
• Methocarbamol demonstrates significant benefits in improving mobility and reducing pain associated with acute LBP.
• The findings support methocarbamol as a valuable therapeutic option for managing acute LBP and associated functional limitations.